Pasithea Therapeutics Corp. Warrant (KTTAW)
$0.01
$0.00
(103.70%)
As on 02-Sep-2026 11:52EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pasithea Therapeutics Corp. Warrant (KTTAW)
| -61.0 | -41.5 | -23.6 | -70.7 | -14.8 | -- | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Pasithea Therapeutics Corp. Warrant (KTTAW)
| -59.2 | 91.2 | -39.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Pasithea Therapeutics Corp. Warrant (KTTAW)
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a... next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. Read more
-
Co-Founder, MD & Executive Chairman
Dr. Lawrence Steinman BA, M.D., Ph.D.
-
Co-Founder, MD & Executive Chairman
Dr. Lawrence Steinman BA, M.D., Ph.D.
-
Headquarters
Miami Beach, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Pasithea Therapeutics Corp. Warrant (KTTAW)
What is the current share price of Pasithea Therapeutics Corp Warrant (KTTAW) Today?
The share price of Pasithea Therapeutics Corp Warrant (KTTAW) is $0.01 (NASDAQ) as of 02-Sep-2026 11:52 EDT. Pasithea Therapeutics Corp Warrant (KTTAW) has given a return of -14.82% in the last 3 years.
What is the current PB & PE ratio of Pasithea Therapeutics Corp Warrant (KTTAW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
0.00 |
0.00 |
2024 |
0.00 |
0.00 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.00 |
2021 |
-0.20 |
0.01 |
What is the 52 Week High and Low of Pasithea Therapeutics Corp Warrant (KTTAW)?
The 52-week high and low of Pasithea Therapeutics Corp Warrant (KTTAW) are Rs 0.12 and Rs 0.00 as of 05-Sep-2026.
What is the market cap of Pasithea Therapeutics Corp Warrant (KTTAW)?
Pasithea Therapeutics Corp Warrant (KTTAW) has a market capitalisation of -- as on 25-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Pasithea Therapeutics Corp Warrant (KTTAW)?
Before investing in Pasithea Therapeutics Corp Warrant (KTTAW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.